Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetr…
| Métrica | MOLN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -76.7% | -39.2% | -37.6% |
| ROA | -60.4% | -30.9% | -29.4% |
| Current Ratio | 8.79 | 2.73 | +6.06 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -60.4% | — |
| ✗Flujo de caja operativo positivo | −CHF 51M | −CHF 59M |
| ✗Rentabilidad sobre activos al alza | -60.4% | -34.1% |
| ✓Caja operativa/activos supera al ROA | -50.2% | ROA -60.4% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 8.79 | 14.31 |
| ✗Sin aumentar el nº de acciones | 37M | 34M |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | 0.00 | 0.03 |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -63.8% |
MOLECULAR PARTNERS AG cotiza a 3.56 USD y tiene una capitalización bursátil de $136M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud